Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insulin injections from daily to once weekly, aiming to ease the treatment burden for the 148 million adults with diabetes in China. Fangzhou integrates this innovative medicine with its AI-driven chronic disease management system to support long-term patient care and adherence. The launch strengthens Fangzhou's collaboration with Novo Nordisk and aligns with China's Healthy China 2030 initiative to improve diabetes treatment accessibility and outcomes.
Novo Nordisk's shares have risen about 27% due to strong commercial growth of oral Wegovy, which holds 89% of new U.S. prescriptions compared to Eli Lilly's 11%. Over 80% of these prescriptions are from new GLP-1 patients, expanding the market rather...
Citi has increased its price target for Novo Nordisk to DKK330 ahead of the company's Q2 results, citing strong sales from the Wegovy pill launch. The broker raised its 2026 sales and operating income estimates by 4-5%, and earnings per share forecas...
Novo Nordisk initiated a share repurchase program starting February 2026, aiming to buy back up to DKK 15 billion of B shares within 12 months. As of July 17, 2026, the company has repurchased approximately 24.96 million B shares at an average price ...
Novo Nordisk's stock has surged 40% since April, driven by the success of its oral Wegovy pill, which is expected to see significant revenue growth by Q2 2026 as it gains international approvals. This growth is notable especially as competitor Eli Li...
